Biomarkers Predicting Complications in ECMO Patients
Author Information
Author(s): Walther Janine, Schmandt Mathias, Muenster Stefan, Kreyer Stefan Franz X., Thudium Marcus, Lehmann Felix, Zimmermann Julian, Putensen Christian, Schewe Jens-Christian, Weller Johannes, Ehrentraut Stefan Felix
Primary Institution: University Hospital Bonn
Hypothesis
Can neuron-specific enolase (NSE) and S100B biomarkers predict outcomes in patients undergoing veno-venous ECMO?
Conclusion
Elevated levels of NSE and S100B are associated with reduced survival and higher rates of poor neurological outcomes in patients on veno-venous ECMO.
Supporting Evidence
- Patients with high NSE levels had significantly reduced median survival times.
- New intracranial pathologies were associated with a significantly reduced overall survival.
- Elevated NSE and S100B levels were independently associated with survival and functional outcomes.
Takeaway
Doctors can use special blood tests to see if patients on a heart-lung machine might have brain problems, which helps them understand how serious the situation is.
Methodology
A retrospective analysis of ECMO patients from 2013 to 2021, assessing serum levels of NSE and S100B and their correlation with neurological outcomes.
Potential Biases
Potential selection bias in neuroimaging and serum marker collection.
Limitations
The study is retrospective and may have selection bias; it did not control for hemolysis affecting biomarker levels.
Participant Demographics
68% male, 32% female, median age 55.6 years.
Statistical Information
P-Value
p<0.0001
Confidence Interval
CI 1.12–2.51 for NSE; CI 2.09–5.06 for S100B
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website